Tag: SIROCCO

AZ’ Fasenra shows long-term efficacy in eosinophilic asthma

by Selina McKee | Sep 18, 2018 | News | 0

AstraZeneca has unveiled data from a Phase III extension trial highlighting the efficacy of biologic Fasenra as an add-on maintenance treatment in patients with severe eosinophilic asthma.

AZ asthma biologic cuts exacerbations, improves symptoms

by Selina McKee | Sep 5, 2016 | News | 0

The Lancet has published data from two trials of AstraZeneca’s biologic benralizumab showing that the drug significantly reduced exacerbations and improved lung function and symptoms in patients with severe eosinophilic asthma.